NCT01591005

Brief Summary

The aim of the project is to demonstrate a fibrinolytic effect of sonothrombolysis (continual transcranial Doppler monitoring) using 2 MegaHertz (MHz) diagnostic probe on the reduction of risk of brain infarctions due to the activation of endogenous fibrinolytic system during carotid endarterectomy (CEA) and carotid stenting (CS). 240 patients indicated for CEA (120 patients) and CS (120 patients) will be enrolled into the study in order to demonstrate a twenty-percent risk reduction of number and volume of brain infarctions detected using MRI examination 24 hours after CEA or CS in 5% level of significance. Patients will be randomized - subgroup 1 will undergo a 60minute non-diagnostic transcranial Doppler (TCD) monitoring during CEA or CS, subgroup 2 will undergo interventions without TCD monitoring. The second aim is to compare number of brain infarctions detected using MRI between CEA and CS patients. Confirmation of the investigators hypothesis that sonothrombolysis is able to activate endogenous fibrinolytic system during CEA or CS with consecutive reduction of the number and volume of brain infarcts, can lead to the increase of the safety of CEA and CS in patients with internal carotid artery stenosis. The investigators can presume that up to 50% of patients indicated for CEA or CS can be treated using these methods in the future. In the Substudy "Risk of brain infarction after carotid endarterectomy and stenting" the the risk of asymptomatic and symptomatic brain infarctions, changes in cognitive functions, as well as morbidity and mortality at 30 days between patients with symptomatic and asymptomatic severe internal carotid artery (ICA) stenoses undergoing elective CEA and CAS will be compared. The sample size of the Substudy was based on an expected 80% difference of new ischemic lesions on DWI-MRI between CEA (estimated prevalence, 30%) and CAS (54%). Pre-study calculations showed that a minimum of 73 patients in each group was needed to reach a significant difference with an alpha value of 0.05 (two-tailed) and a beta value of 0.8 assuming that 15% of subjects would be lost to follow-up or refuse to participate in the study.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
242

participants targeted

Target at P50-P75 for phase_3

Timeline
Completed

Started Oct 2010

Longer than P75 for phase_3

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

October 1, 2010

Completed
1.6 years until next milestone

First Submitted

Initial submission to the registry

April 23, 2012

Completed
10 days until next milestone

First Posted

Study publicly available on registry

May 3, 2012

Completed
2.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 1, 2014

Completed
11 months until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2015

Completed
1.3 years until next milestone

Results Posted

Study results publicly available

September 8, 2016

Completed
Last Updated

September 8, 2016

Status Verified

July 1, 2016

Enrollment Period

3.8 years

First QC Date

April 23, 2012

Results QC Date

December 22, 2015

Last Update Submit

July 24, 2016

Conditions

Keywords

sonolysiscarotidendarterectomystenting

Outcome Measures

Primary Outcomes (1)

  • Participants With a New Brain Infarction Detected Using Magnetic Resonance

    The number of participants with a new brain infarctions in sonolysis group detected using magnetic resonance examination 24 hours after carotid endarterectomy or carotid stenting. Substudy: The number of participants with a new brain infarctions on brain diffusion-weighted magnetic resonance imaging performed 24 hours after intervention in carotid endarterectomy and carotid stenting groups.

    24 hours after intervention

Secondary Outcomes (5)

  • Participants With a New Brain Infarctions Detected Using Magnetic Resonance in Endarterectomy and Stenting Groups

    24 hours after intervention

  • Cognitive Decline

    24 hours after intervention

  • Number of Participants With Clinical Manifested Brain Infarction

    24 hours and 30 days after intervention

  • Number of Participatns With New Ipsilateral Brain Infarctions Detected Using MRI in Endarterectomy and Stenting Groups

    24 hours after intervention

  • Number of Participants With Clinical Vascular Event or Death

    30 days after intervention

Other Outcomes (1)

  • Number of Participants With Complications

    24 hours and 30 days after intervention

Study Arms (4)

CEA with sonolysis

EXPERIMENTAL

endarterectomy with sonolysis (continual transcranial Doppler monitoring)

Procedure: sonolysisProcedure: endarterectomy

CEA without sonolysis

PLACEBO COMPARATOR

endarterectomy without sonolysis

Procedure: endarterectomy

carotid stenting with sonolysis

EXPERIMENTAL

carotid stenting with sonolysis (continual transcranial Doppler monitoring)

Procedure: sonolysisProcedure: carotid stenting

carotid stenting without sonolysis

PLACEBO COMPARATOR

carotid stenting without sonolysis

Procedure: carotid stenting

Interventions

sonolysisPROCEDURE

continual transcranial Doppler monitoring with max. diagnostic intensity for 60 minutes

Also known as: sonothrombolysis, sonothrombotripsy
CEA with sonolysiscarotid stenting with sonolysis

carotid endarterectomy

Also known as: carotid endarterectomy
CEA with sonolysisCEA without sonolysis

percutaneous transluminal angioplasty and stenting

Also known as: percutaneous transluminal angioplasty and stenting
carotid stenting with sonolysiscarotid stenting without sonolysis

Eligibility Criteria

Age40 Years - 80 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • stenosis of internal carotid artery
  • indication to endarterectomy or stenting
  • age 40-80 years
  • sufficient temporal bone window for TCD with detectable blood flow in MCA
  • independent patient (modified Rankin score 0-2)
  • informed consent signed by the patient.

You may not qualify if:

  • contraindication to MRI examination (pace-maker, implanted metal material, claustrophobia)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University Hospital Ostrava

Ostrava, Czech Republic, 70852, Czechia

Location

Related Publications (2)

  • Skoloudik D, Kuliha M, Hrbac T, Jonszta T, Herzig R; SONOBUSTER Trial Group. Sonolysis in Prevention of Brain Infarction During Carotid Endarterectomy and Stenting (SONOBUSTER): a randomized, controlled trial. Eur Heart J. 2016 Oct 21;37(40):3096-3102. doi: 10.1093/eurheartj/ehv492. Epub 2015 Sep 28.

  • Kuliha M, Roubec M, Prochazka V, Jonszta T, Hrbac T, Havelka J, Goldirova A, Langova K, Herzig R, Skoloudik D. Randomized clinical trial comparing neurological outcomes after carotid endarterectomy or stenting. Br J Surg. 2015 Feb;102(3):194-201. doi: 10.1002/bjs.9677. Epub 2014 Dec 16.

Related Links

MeSH Terms

Conditions

Carotid Stenosis

Interventions

EndarterectomyEndarterectomy, CarotidAngioplastyStents

Condition Hierarchy (Ancestors)

Carotid Artery DiseasesCerebrovascular DisordersBrain DiseasesCentral Nervous System DiseasesNervous System DiseasesArterial Occlusive DiseasesVascular DiseasesCardiovascular Diseases

Intervention Hierarchy (Ancestors)

Vascular Surgical ProceduresCardiovascular Surgical ProceduresSurgical Procedures, OperativeCatheterizationTherapeuticsEndovascular ProceduresMinimally Invasive Surgical ProceduresInvestigative TechniquesProstheses and ImplantsEquipment and Supplies

Limitations and Caveats

Serial follow-up MRI was not done. A software package for mapping of brain infarction volume was not used. Single-centre investigation with mandatory use of brain protection device during carotid stenting and shunt during carotid endarterectomy.

Results Point of Contact

Title
Prof. David Skoloudik, MD, Ph.D.
Organization
University Hospital Ostrava

Study Officials

  • David Skoloudik, MD, PhD

    University Hospital Ostrava

    PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee
Yes

Study Design

Study Type
interventional
Phase
phase 3
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Vaclav Prochazka, MD, PhD, MSc

Study Record Dates

First Submitted

April 23, 2012

First Posted

May 3, 2012

Study Start

October 1, 2010

Primary Completion

July 1, 2014

Study Completion

June 1, 2015

Last Updated

September 8, 2016

Results First Posted

September 8, 2016

Record last verified: 2016-07

Locations